Plasma-Derived Therapies Market Size, Share, Growth and Forecast, 2025-2035

Immunoglobulins anchor spending on plasma medicines

The global plasma-derived therapies market was valued at USD 18.91 billion in 2025 and is projected to increase from USD 20.21 billion in 2026 to USD 36.80 billion by 2035, registering a CAGR of 6.89% during 2026–2035. Demand comes from patients who need lifelong immunoglobulin replacement for immune deficiency, regular infusions for nerve disorders, clotting factors for bleeding disorders and albumin for critical care. North America held the largest regional share, 44.0% in 2025, because the United States runs the largest compensated plasma collection network and pays the highest prices for these medicines. Asia Pacific is the fastest-growing region at 8.15% a year, as China, Japan, South Korea and India widen diagnosis and treatment access. The commercial picture shifted after 2024, when U.S. regulators added nerve disorder indications for immunoglobulins and approved new brands and higher-yield production processes. As a result, growth now depends on how much plasma companies can collect and convert into finished product.

Which plasma medicines does this analysis count?

The analysis counts immunoglobulins given by vein or under the skin, albumin, plasma-derived clotting factors and other plasma proteins such as fibrinogen concentrate, alpha-1 antitrypsin and hyperimmune globulins. Hospitals, infusion centers, specialty pharmacies and national tenders purchase these medicines from fractionation companies that collect or buy human plasma.

Recombinant clotting factors, gene therapies and non-factor antibodies sit outside the value counted here, although they shape demand in bleeding disorders. The value chain runs from donor centers through testing, pooling, fractionation and fill-finish to distributors, hospitals and home infusion providers.

Immunoglobulin and immune deficiency care hold the lead

What keeps immunoglobulin ahead of albumin and factors?

Based on product type, the market is categorized into immunoglobulin, albumin, coagulation factors and others. Immunoglobulin led with a 54.0% share of 2025 value, because patients with immune deficiency and nerve disorders need regular infusions for years. This product type also grows fastest at 7.35% a year, as regulators add new indications and brands. Coagulation factors grow more slowly, because non-factor antibodies now compete in high-income countries.

Why does immune deficiency care lead applications?

Based on application, the market is categorized into primary immunodeficiency disease, hemophilia, idiopathic thrombocytopenic purpura and others. Primary Immunodeficiency Disease led with a 38.0% share of 2025 value, because affected patients need lifelong immunoglobulin replacement. This application also grows fastest at 7.45% a year, as earlier genetic diagnosis adds patients. The others group includes nerve disorders, critical care albumin use and rare bleeding conditions.

Immune deficiency care and nerve disorder use lift demand

How does immune deficiency care sustain demand?

Immune deficiency care is the largest demand driver, because most patients need immunoglobulin replacement every few weeks for life. The National Institute of Allergy and Infectious Diseases reports more than 200 forms of primary immune deficiency disease, affecting approximately 500,000 people in the United States. Many of these patients are diagnosed in adulthood after years of repeated infections, which adds new starts each year. Primary immunodeficiency disease held 38.0% of 2025 value, the largest share of any clinical use in the market. Specialists also prescribe immunoglobulin for secondary immune deficiency linked to blood cancers and their treatment, which widens the patient pool. As a result, immune deficiency disorder treatment remains the core volume base for every fractionator in the market.

Why are nerve disorder indications lifting immunoglobulin volumes?

Nerve disorder indications lift volumes, because patients with chronic inflammatory demyelinating polyneuropathy receive high doses on a regular schedule. In January 2024, Takeda received FDA approval for Gammagard Liquid in adults with this condition, making it the only intravenous product approved in the United States for several neuromuscular indications. Earlier in January 2024, the FDA also approved HyQvia as maintenance treatment for the same condition, with infusions every 2, 3 or four weeks, which can be self-administered at home after appropriate training. These approvals add a second large patient group beside immune deficiency care in hospitals and clinics. In turn, intravenous immunoglobulin use per patient keeps rising in North America and Europe.

Download Free Sample

How is collection capacity supporting growth?

Collection capacity supports growth, because every gram of immunoglobulin depends on donated plasma. In March 2025, Kamada announced the opening of a new plasma collection center in San Antonio, Texas, adding supply for its specialty products. In May 2024, Terumo Blood and Cell Technologies received FDA 510(k) clearance for an individualized nomogram on its Rika plasma donation system, which sets collection volume from donor height, weight and hematocrit. The WHO reports that only around 27% of plasma sent for fractionation is recovered from whole blood donations, so dedicated plasma donation supplies most of the rest. As a result, apheresis equipment upgrades and new centers translate directly into more finished product.

Why does uneven access worldwide create room for growth?

Uneven access creates room for growth, because many countries still collect far less blood and plasma than they need. The World Health Organization reports 120.4 million blood donations a year, yet 36% come from high-income countries that hold 15% of the world population. The median donation rate is 28.9 per 1,000 people in high-income countries, against 4.5 in low-income countries. This gap means demand for immunoglobulins and albumin in middle-income countries remains well above supply. In turn, hospitals in China, India and Southeast Asia that widen diagnosis and intensive care capacity add steady new demand for immunoglobulins, albumin and clotting factors.

Yield gains, new brands and local fractionation

How are yield gains raising output per liter?

Fractionators are shifting toward yield gains, because new plants take years to build while process changes raise output quickly. In April 2025, ADMA Biologics announced FDA approval of a yield enhancement process that increases immunoglobulin output by approximately 20% from the same starting plasma volume, for both its Asceniv and Bivigam brands. By its second-quarter 2025 update, the company had started commercial-scale manufacturing with the new process, and initial batches delivered the expected gain. The WHO reports that around 21.5 million liters of plasma from 36 reporting countries were fractionated in the latest year. As a result, even small yield improvements across that volume add meaningful supply.

Is a rise in new immunoglobulin brands widening supply?

A rise in new U.S. brands is widening supply, because several fractionators have recently cleared FDA review for intravenous products. In June 2024, Grifols said its Biotest unit received FDA approval for Yimmugo, with a U.S. launch planned for the second half of 2024. Kedrion Biopharma followed in September 2025 with U.S. approval of Qivigy, its 10% intravenous immunoglobulin for adults living with primary humoral immunodeficiency. Kedrion said the approval reflects more than 10 years of internal investment to bring its own intravenous product to market. Because immunoglobulin is the largest product type, new entrants target the biggest pool of spending. In turn, hospitals and specialty pharmacies gain more supplier choice and some price leverage, while makers of subcutaneous immunoglobulin respond with home dosing options.

Download Free Sample

Where can domestic fractionation programs open new business?

Domestic fractionation programs are a clear opening for suppliers, because the WHO reports that only 49 of 168 reporting countries produce plasma medicines from their own plasma. A total of 119 countries reported that all such products are imported or that none were used. The volume of plasma for fractionation ranged from 0.3 to 55.4 liters per 1,000 people, with a median of 5.4 liters. These gaps push governments toward toll manufacturing and technology transfer agreements, which convert locally collected plasma into immunoglobulin and albumin without a full domestic plant. As a result, fractionators with spare plant capacity can win long-term national contracts in Asia, Latin America and the Middle East.

Can specialty plasma proteins create premium niches?

Specialty plasma proteins create a premium opening, because rare bleeding conditions need purified concentrates that hospitals cannot prepare locally. In December 2025, the FDA approved Grifols' Fesilty fibrinogen concentrate for acute bleeding in congenital fibrinogen deficiency. Octapharma then said in January 2026 that the FDA cleared a 2-gram fibryga presentation for patients with acquired fibrinogen deficiency. Larger vials simplify dosing during cardiac surgery and trauma, when clinicians need fibrinogen replacement quickly. The WHO notes that safe supply of immunoglobulins and coagulation factors is needed to treat serious conditions worldwide, which supports investment in specialty concentrates. In turn, coagulation factor concentrates can replace part of the cryoprecipitate still used in many hospitals.

Donor supply and non-factor rivals limit growth

Can donors keep pace with immunoglobulin demand?

Donor numbers struggle to keep pace, because each immunoglobulin course needs plasma from many separate donations. The WHO reports that 55 countries collect fewer than 10 donations per 1,000 people, which leaves their hospitals reliant on imported vials. Donation volumes also dip during holidays, epidemics and strong labor markets, when fewer adults visit centers. As a result, immunoglobulin and albumin shortages can persist for months even when prescribers have patients waiting.

Why can fractionators not respond quickly to shortages?

Fractionators cannot respond quickly, because each plasma lot passes through donor testing, inventory hold, pooling, fractionation and fill-finish before shipment. That chain often spans many months, so a sudden rise in nerve disorder prescriptions cannot be met from next quarter's collections. A new fractionation plant also takes years to build and inspect. Release rules vary by country, which complicates moving finished lots from one region to another.

Do non-factor hemophilia therapies erode demand?

Non-factor therapies erode part of the hemophilia demand, because they avoid donor dependence and allow less frequent dosing. The FDA approved Hympavzi in October 2024, Alhemo in December 2024 and Qfitlia in March 2025 for bleeding prevention in hemophilia A or B. Patients in high-income countries increasingly switch to these options for routine prophylaxis. However, plasma-derived factors keep a role in public tenders and for patients with inhibitors in middle-income countries.

Will new oral options reduce immunoglobulin use in ITP?

New oral options may reduce immunoglobulin use in idiopathic thrombocytopenic purpura, because physicians prefer tablets for long-term care. In August 2025, the FDA approved Wayrilz for persistent or chronic immune thrombocytopenia that has not responded well to immunoglobulins, anti-D therapy or corticosteroids. However, immunoglobulin remains the standard rescue treatment when platelet counts fall quickly before surgery or during bleeding. This shift still limits long-term immunoglobulin volume growth in idiopathic thrombocytopenic purpura over the forecast period.

U.S. plasma centers keep North America ahead

How does U.S. plasma collection keep North America ahead?

North America held a 44.0% share of 2025 value and grows at 6.55% a year through 2035. The United States permits compensated plasma donation, and Kamada opened a new collection center in San Antonio, Texas, in March 2025. Neurologists prescribe high immunoglobulin doses for chronic inflammatory demyelinating polyneuropathy, which lifts spending per patient. However, Yimmugo, Qivigy and higher-yield production add supply that tempers prices.

What makes Asia Pacific the fastest-growing region?

Asia Pacific held a 21.0% share of 2025 value and is the fastest-growing region at 8.15% a year. China and South Korea run domestic fractionation industries, and South Korea hosts established producers such as SK Plasma. Japan has a mature hospital market for immunoglobulin in immune deficiency and nerve disorders. India and Southeast Asia still import much of their immunoglobulin and albumin, so rising diagnosis there translates into new import demand.

Download Free Sample

Why does Europe import part of its immunoglobulin supply?

Europe held a 26.0% share of 2025 value and grows at 6.15% a year, the slowest pace of the five regions. Many European health systems rely on unpaid donors, and several countries use more immunoglobulin than their own plasma can produce. National tender systems in several countries keep albumin and factor prices low. However, Octapharma, Kedrion, Biotest and Bio Products Laboratory run major fractionation plants in Europe.

How are Latin American tenders shaping demand?

Latin America held a 5.0% share of 2025 value and grows at 7.45% a year through 2035. Public buyers in Brazil, Mexico and Argentina purchase immunoglobulin, albumin and factor concentrates through tenders that reward low prices. Some governments are studying toll fractionation of locally collected plasma to cut import bills.

Where do the Middle East and Africa source supply?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 7.55% a year through 2035. Gulf hospitals import immunoglobulin and albumin from European and U.S. fractionators. Across much of Africa, low donation rates and gaps in cold storage keep immune deficiency and bleeding disorder patients undertreated.

Download Free Sample

Approvals and capacity moves since 2024

Collection, purification and dosing tools to watch

• Individualized collection nomograms calculate a safe plasma volume from each donor's height, weight and hematocrit, so centers collect more per visit.
• Immunoglobulin yield enhancement recovers a larger share of IgG during fractionation, as ADMA Biologics showed with its roughly 20% output gain.
• Multi-step chromatography strips unwanted proteins and lowers impurities in immunoglobulin and fibrinogen products before fill-finish.
• Hyaluronidase-facilitated subcutaneous infusion lets patients take monthly immunoglobulin volumes under the skin at home, as HyQvia does in CIDP.

Fractionators compete on plasma access and yield

Rivalry in plasma medicines turns on who controls plasma, because immunoglobulin output rises only as fast as collections and yield. CSL Behring, Grifols, Takeda and Octapharma own donor center networks, large fractionation plants and worldwide sales teams. Grifols also controls Biotest AG, whose Yimmugo gained U.S. approval in 2024. Kedrion and Bio Products Laboratory sell immunoglobulins, albumin and clotting factors from European plants into many regions. ADMA Biologics sells specialty immunoglobulins in the United States and runs its own plasma centers, while Kamada focuses on hyperimmune globulins and specialty plasma proteins. SK Plasma serves Asian buyers from South Korea, and Pfizer competes in hemophilia care with alternatives to plasma-derived factors. Each of these companies still depends on donor turnout and the cost of each liter collected.

Companies profiled and their roles in this market

Plasma supply sets the pace of growth to 2035

Credence Research expects collections and yield, rather than prescriber demand, to cap how fast plasma medicine sales rise through 2035. The market advances at 6.89% a year, with immune deficiency care and CIDP prescriptions supplying most new volume. Immunoglobulin, fibrinogen concentrate and contract fractionation deals offer the best openings. Fractionators that own donor centers and adopt processes like ADMA Biologics' yield upgrade should defend margins, while buyers of third-party plasma face rising input costs and tighter margins as competition for donors intensifies.

How Credence Research sized plasma medicine spending

The base year is 2025 and the forecast runs from 2026 to 2035. Market values come from the Credence Research model, which sums spending by product type and application across five regions. Splits by region and segment are Credence Research estimates, informed by World Health Organization blood supply data, NIAID disease statistics, FDA decisions, company releases and SEC filings. This edition relies on published sources only and did not use primary interviews or surveys.

Immunoglobulin and specialty protein outlook to 2035

The plasma-derived therapies market is projected to reach USD 36.80 billion by 2035, with immunoglobulin and Asia Pacific supplying most of the added value. Immune deficiency and CIDP patients will keep infusion volumes climbing, while non-factor hemophilia drugs hold back clotting factor sales. Nomogram-guided collection and yield upgrades should stretch each liter further over the decade. North America keeps the highest spending per patient, and Asia Pacific adds the largest number of new patients. As a result, donor access and plant capacity will separate leaders from followers.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.